Singapore Medical Group H1 earnings more than double on demand in diagnostics, aesthetics
THE H1 net profit of Singapore Medical Group 5OT (SMG) more than doubled to S$7.2 million for the half-year period ended June 30, up from S$3.5 million a year ago due to rising demand in the group's aesthetics, Lasik and diagnostic imaging-related services.
The Catalist-listed group said its half-yearly profit was 5.1 per cent higher compared to pre-Covid-19 levels in H1 FY2019.
SMG's executive director and chief executive officer Beng Teck Liang said that the results came as "a bit of a surprise" and attributed the increased demand for procedures such as health check-ups, plastic surgery and Lasik by Singaporeans, who have been unable to leave for other countries like Malaysia and Korea to complete these treatments.
